Dedicated to enabling long term patient access to drisapersen as novel treatment for DMD: Hans Schikan, CEO Prosensa




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Dedicated to enabling long term patient access to drisapersen as novel treatment for DMD: Hans Schikan, CEO Prosensa
Released on: May 01, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview, filmed in London, Fintan Walton talks to Hans Schikan, CEO of Prosensa.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed in London, Fintan Walton talks to Hans Schikan, CEO of Prosensa. Prosensa is a biotechnology company focused on the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a focus on neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy, Myotonic Dystrophy and Huntington’s disease.
In this interview, filmed in London, Fintan Walton talks to Hans Schikan, CEO of Prosensa. Prosensa is a biotechnology company focused on the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a focus on neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy, Myotonic Dystrophy and Huntington’s disease. Following positive feedback from patients and investigators regarding the willingness and desire of patients to go back on drisapersen and encouraging analyses of its clinical trial data, Prosensa has confirmed that it will re-dose an initial cohort of boys in the third quarter of 2014. The Company has made significant progress in the transition of the program from its former partner, GSK, and expects to communicate on a regulatory path forward for drisapersen before the end of June.
Hans Schikan
Prosensa
Prosensa
Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular disorders.